A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Trial Profile

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs MEDI 7247 (Primary)
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 05 Jun 2018 As of February 6, 2018, 19 patients have been enrolled (AML, n = 11; DLBCL, n = 6; MM, n = 2) as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 10 Jul 2017 Planned End Date changed from 13 Jul 2020 to 7 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top